Bank of America Corp DE Makes New $214.50 Million Investment in Halozyme Therapeutics, Inc. $HALO

Key Points

• Bank of America acquired a new $214.5 million stake in Halozyme Therapeutics during the second quarter, purchasing 2.74 million shares and owning 2.41% of the company. Institutional investors collectively own 97.79% of HALO.
• Halozyme reported stronger-than-expected quarterly results, with EPS of $2.28 versus the $1.79 consensus and revenue of $481 million, up 47.7% year over year. The company issued fiscal 2026 EPS guidance of $8.65 to $9.00.
• Analysts maintain a generally positive outlook, with nine Buy ratings, three Holds, and one Sell; the consensus rating is Moderate Buy. Shares opened at $108.44, near the company’s 12-month high of $111.15.

Bank of America Corp DE purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 2,740,561 shares of the biopharmaceutical company's stock, valued at approximately $214,504,000. Bank of America Corp DE owned 2.41% of Halozyme Therapeutics at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of HALO. Measured Wealth Private Client Group LLC lifted its stake in shares of Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 124 shares during the period. Twin Capital Management Inc. raised its position in Halozyme Therapeutics by 1.4% in the first quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company's stock worth $738,000 after acquiring an additional 161 shares during the period. Pzena Investment Management LLC raised its position in Halozyme Therapeutics by 4.2% in the fourth quarter. Pzena Investment Management LLC now owns 4,278 shares of the biopharmaceutical company's stock worth $288,000 after acquiring an additional 171 shares during the period. First Citizens Bank & Trust Co. raised its position in Halozyme Therapeutics by 2.0% in the first quarter. First Citizens Bank & Trust Co. now owns 9,088 shares of the biopharmaceutical company's stock worth $587,000 after acquiring an additional 175 shares during the period. Finally, Nations Financial Group Inc. IA ADV boosted its stake in shares of Halozyme Therapeutics by 1.2% during the 1st quarter. Nations Financial Group Inc. IA ADV now owns 15,177 shares of the biopharmaceutical company's stock worth $981,000 after acquiring an additional 183 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Up 2.1%

Shares of HALO opened at $108.44 on Thursday. The business's 50 day moving average is $95.33 and its 200 day moving average is $77.80. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics, Inc. has a 12-month low of $61.22 and a 12-month high of $111.15. The company has a market capitalization of $12.31 billion, a PE ratio of 32.37, a price-to-earnings-growth ratio of 0.40 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm's revenue for the quarter was up 47.7% compared to the same quarter last year. During the same period in the prior year, the company posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Research analysts expect that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on HALO shares. TD Cowen boosted their price objective on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research note on Monday, August 31st. Benchmark reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Wells Fargo & Company upped their price target on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an "equal weight" rating in a research report on Friday, August 7th. Finally, HC Wainwright reiterated a "buy" rating and issued a $115.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, September 2nd. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Halozyme Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $91.20.

Insider Buying and Selling

In related news, Director Mahesh Krishnan sold 7,304 shares of the firm's stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the transaction, the director directly owned 14,462 shares of the company's stock, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the sale, the director owned 40,418 shares in the company, valued at approximately $4,154,970.40. This represents a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 72,478 shares of company stock worth $7,370,004. 2.50% of the stock is owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company's primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.